Advertisement

---

SANOFI

Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes

[2013-06-22] - -- Lixisenatide decreased HbA1c by reducing PPG when added to basal insulin with or without oral anti-diabetic agents --


Sanofi Announces Positive Phase 3 Results for Investigational New Insulin U300

[2013-06-22] - - EDITION I demonstrated similar blood sugar control with fewer night-time low blood sugar events compared to Lantus® -
- Topline results of EDITION II consistent with EDITION I findings -


Sanofi US and Joslin Diabetes Center Announce Results from Multicultural Outreach Pilot at American Diabetes Association Scientific Sessions

[2013-06-22] -


Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis

[2013-05-17] -


Advertisement
Most read: scientific news

More:

---


---
Follow us...

google plus Facebook twitter Newsletter

---


---

Plan du site

Actualités

Actualités

Actualités

Réglementaire

Emploi

Annuaires

Dictionnaire

Divers